title: Active oxygen species in formation of acute gastric mucosal lesions induced by thermal injury in rats.
abstract: Active oxygen species generated by circulating leukocytes and released from the gastric mucosa were measured in the process of acute gastric mucosal lesion formation after thermal injury in rats. Alterations of luminol-dependent chemiluminescence activities generated by leukocytes obtained from the gastric vein and the inferior vena cava were approximately same. A decrease in chemiluminescence activity 15 min after thermal injury and a significant increase in chemiluminescence activity 5 hr after thermal injury were observed in leukocytes from both veins. From 15 min to 12 hr after thermal injury, luciferin-dependent chemiluminescence activities were significantly higher than that of the control group. Oral administration of rebamipide resulted in decreased mucosal lesion formation. Rebamipide, an antiulcer agent that protects the mucosa from damage in various animal models decreased chemiluminescence activities only released from the gastric mucosa but not from circulating leukocytes. These results suggest that two different pathways of active oxygen species formation may exist in the pathogenesis of acute gastric mucosal lesions after thermal injury.
authors.affiliation: Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yoshida
authors.forename: T
authors.initials: T
authors.lastname: Kitahora
authors.forename: G
authors.initials: G
authors.lastname: Wakabayashi
authors.forename: H
authors.initials: H
authors.lastname: Tashiro
authors.forename: H
authors.initials: H
authors.lastname: Ono
authors.forename: Y
authors.initials: Y
authors.lastname: Otani
authors.forename: M
authors.initials: M
authors.lastname: Shimazu
authors.forename: T
authors.initials: T
authors.lastname: Kubota
authors.forename: K
authors.initials: K
authors.lastname: Kumai
authors.forename: M
authors.initials: M
authors.lastname: Kitajima
mesh_terms: D000208:Acute Disease; D000409:Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000704:Analysis of Variance; D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002056:Burns / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism*; D004353:Drug Evaluation, Preclinical; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism*; D007962:Leukocytes / Q000187:drug effects / Q000378:metabolism; D008163:Luminescent Measurements; D008297:Male; D015363:Quinolones / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism*; D013276:Stomach Ulcer / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism*; D013997:Time Factors
chemical_list: D000897:Anti-Ulcer Agents; D015363:Quinolones; D017382:Reactive Oxygen Species; C052785:rebamipide; D000409:Alanine